Oramed Pharmaceuticals Company Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Its product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes; and ORA-D-013-1 and ORA-D-013-2, which have completed phase III clinical trial for the treatment of type 2 diabetes.

The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.

Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Inc.

Country	United States
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Nadav Kidron

Contact Details

Address: 1185 Avenue of the Americas New York, Delaware 10036 United States
Phone	844 967 2633
Website	oramed.com

Stock Details

Ticker Symbol	ORMP
Exchange	Tel Aviv Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US68403P2039
SIC Code	2836

Key Executives

Name	Position
Nadav Kidron Esq.	President, Chief Executive Officer and Executive Chairman
Avraham Gabay	Chief Financial Officer, Treasurer and Secretary
Dr. Miriam Kidron Ph.D.	Chief Scientific Officer and Director
Joshua Hexter	Chief Operating and Business Officer